Radioactive drug aims to shrink aggressive prostate tumors before surgery

NCT ID NCT06798558

Recruiting now Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether a single dose of Lu-177-PSMA-617 (Pluvicto), a radioactive drug that targets prostate cancer cells, can shrink or eliminate high-risk prostate tumors before surgery. About 54 men with aggressive prostate cancer (Gleason score 8 or higher) will receive the drug and then undergo prostatectomy. The main goal is to see if the cancer is less advanced after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu-177-PSMA-617 (Pluvicto), a radioactive drug that targets prostate cancer cells
What this could lead to: If successful, this could offer a new way to shrink aggressive prostate tumors before surgery, potentially reducing the risk of cancer returning.
What could go wrong: This is a small, early-phase trial with only 54 participants, so results may not apply to all patients. The drug is radioactive and may cause side effects like dry mouth, fatigue, or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20057, United States
MedStar Washington Hospital Center
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.